BioCentury
ARTICLE | Financial News

Roivant’s urology subsidiary files for $150M IPO

July 13, 2018 11:51 PM UTC

Urovant Sciences Ltd. (London, U.K) proposed Friday to raise up to $150 million in an IPO on NASDAQ underwritten by J.P. Morgan, Jefferies and Cowen. The urology play is a wholly owned subsidiary of Roivant Sciences GmbH (Basel, Switzerland), which will be Urovant's controlling shareholder following the offering...

BCIQ Company Profiles

Roivant Sciences Ltd.